Management of stage T1b (A2) and stage T1c adenocarcinoma of the prostate

B. R. Konety, R. R. Bahnson

Research output: Contribution to journalReview articlepeer-review

Abstract

The management of stage T1b (A2) and T1c adenocarcinoma of the prostate is somewhat controversial. With the widespread use of serum prostate-specific antigen (PSA) determinations, an increasing number of these cancers are likely to be diagnosed. Hence, it is important to formulate a cogent management strategy for these patients, because a large percentage of them can be expected to have clinically and pathologically localized disease. Expectant observation with deferred treatment, radical prostatectomy, radiation therapy (external beam or brachytherapy), and cryosurgical ablation are all primary therapeutic options that have individual merit. In this review, we attempt to analyze the results of the various treatment options for these patients and evolve a practical approach towards their management.

Original languageEnglish (US)
Pages (from-to)183-194
Number of pages12
JournalSeminars in Urologic Oncology
Volume14
Issue number3
StatePublished - Aug 27 1996

Keywords

  • Stage T1b/c prostate cancer
  • prostate cancer
  • treatment

Fingerprint Dive into the research topics of 'Management of stage T1b (A2) and stage T1c adenocarcinoma of the prostate'. Together they form a unique fingerprint.

Cite this